Cerebrovascular Disorders
Recent clinical, regulatory, research and industry developments relating to this disease.
Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis.
Mechanisms of cognitive dysfunction in CKD.
A population-based study of cardiovascular disease mortality risk in US cancer patients.
Epidemiology of Vascular Dementia.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q3 2027.
- Q3 2027Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke (EXTEND-AGNES TNK)
- Q3 2028Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: A Phase I Drug Pilot Research Plan
- Q1 2030a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)
Clinical MilestonesViewHide
- 2026-05-18Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke (EXTEND-AGNES TNK)Results expected Q3 2027
- 2026-04-23Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: A Phase I Drug Pilot Research PlanResults expected Q3 2028
- 2026-04-16a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)Results expected Q1 2030
- 2026-05-18ClinicalPost-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke (EXTEND-AGNES TNK)Results expected Q3 2027
- 2026-04-23ClinicalInhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: A Phase I Drug Pilot Research PlanResults expected Q3 2028
- 2026-04-16Clinicala Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)Results expected Q1 2030
- 2026-01-31ClinicalMulticenter, Randomized, Double-blind, Placebo-controlled Comparative Study of the Efficacy and Safety of the Drug Dimephosphon®, Concentrate for Solution for Intravenous Administration, 1 g, in Acute Ischemic Stroke PatientsPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes4
- Cardiovascular Diseases1
- Cerebrovascular Disorders1
- Diabetes Mellitus, Type 21
- Postoperative Complications1
Leading journals6
- Arteriosclerosis, thrombosis, and vascular biology1
- BMJ (Clinical research ed.)1
- Circulation1
- European heart journal1
- European journal of clinical investigation1
- Nature reviews. Nephrology1
Leading researchers8
- Ahmadi N1
- Aimo A1
- Bluethmann SM1
- Caforio ALP1
- Capasso G1
- Carbone F1
- Cook EF1
- Debette S1
Affiliations (unnormalised)6
- Brigham and Women's Hospital and Harvard Medical School1
- Clinical Neuroscience1
- Department of Clinical Therapeutics1
- Early Clinical Development1
- Erasmus University Medical Center1
- First Clinic of Internal Medicine1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Cerebrovascular disorders are a spectrum of conditions caused by impaired blood flow in the brain. They can involve arteries or veins in the cerebrum, cerebellum, or brain stem, and include major categories such as intracranial arteriovenous malformations, brain ischemia, and cerebral hemorrhage.
The grounding supports vascular causes rather than a single aetiology. It specifically notes atherosclerosis, arterio(lo)sclerosis, microinfarcts, and amyloid angiopathy as important vascular components in cerebrovascular-related cognitive decline, and it also includes intracranial arteriovenous malformations as a major category.
The core mechanism is disruption of cerebral blood flow, which can produce ischemia or hemorrhage depending on the vessels and brain region involved. The literature also links cerebrovascular disease to white matter injury, macrovascular and microvascular damage, and small-vessel lesions such as microinfarcts, which can contribute to cognitive decline.
Stroke is a major associated risk state, and the literature indicates that risk of dementia is increased after stroke. White matter hyperintensities on brain MRI are associated with higher risk of stroke, cognitive decline, dementia, and death, and chronic kidney disease is associated with increased risk of dementia and mild cognitive impairment in the setting of vascular brain injury.
The supplied grounding only supports treatment at the drug-class level. It indicates drug therapy is a relevant management modality, and mentions cardiovascular risk-factor targeting with antihypertensive drugs and GLP-1 receptor agonists in the context of cerebrovascular disease prevention and related vascular risk reduction.
AI-generated summary grounded in MeSH and 5 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.